Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics (PLRX) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. Bernard Coulie, M.D., Ph.D., the company's President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.
Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of Pliant's website at www.PliantRx.com. The presentation recording will remain accessible on the website for 30 days after the event concludes.
Pliant Therapeutics (PLRX) ha annunciato la sua partecipazione al prossimo 43° Annual J.P. Morgan Healthcare Conference. Bernard Coulie, M.D., Ph.D., Presidente e Amministratore Delegato dell'azienda, terrà una presentazione martedì 14 gennaio 2025, alle 13:30 ora del Pacifico presso il Westin St. Francis Hotel a San Francisco.
Investitori e stakeholder interessati possono accedere alla presentazione tramite un webcast dal vivo disponibile nella sezione Investitori e Media del sito di Pliant all'indirizzo www.PliantRx.com. La registrazione della presentazione sarà accessibile sul sito per 30 giorni dopo la conclusione dell'evento.
Pliant Therapeutics (PLRX) ha anunciado su participación en la próxima 43.ª Conferencia Anual de Salud de J.P. Morgan. Bernard Coulie, M.D., Ph.D., Presidente y Director Ejecutivo de la compañía, presentará una charla el martes 14 de enero de 2025, a la 1:30 p.m. Hora del Pacífico en el Hotel Westin St. Francis de San Francisco.
Los inversionistas y partes interesadas pueden acceder a la presentación a través de una transmisión web en vivo disponible en la sección de Inversionistas y Medios del sitio web de Pliant en www.PliantRx.com. La grabación de la presentación estará disponible en el sitio durante 30 días después de que concluye el evento.
Pliant Therapeutics (PLRX)는 다가오는 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참석할 것이라고 발표했습니다. Bernard Coulie, M.D., Ph.D., 회사의 사장이자 CEO가 2025년 1월 14일 화요일, 오후 1시 30분 태평양 표준시에 샌프란시스코의 웨스틴 세인트 프랜시스 호텔에서 발표를 할 예정입니다.
관심 있는 투자자와 이해관계자는 Pliant의 웹사이트 www.PliantRx.com의 투자자 및 미디어 섹션을 통해 실시간 웹캐스트를 통해 발표를 볼 수 있습니다. 발표 녹화는 이벤트 종료 후 30일 동안 웹사이트에서 볼 수 있습니다.
Pliant Therapeutics (PLRX) a annoncé sa participation à la prochaine 43e Conférence Annuelle de Santé J.P. Morgan. Bernard Coulie, M.D., Ph.D., Président et Directeur Général de l'entreprise, fera une présentation le mardi 14 janvier 2025, à 13h30, heure du Pacifique à l'Hôtel Westin St. Francis à San Francisco.
Les investisseurs et parties prenantes intéressés peuvent accéder à la présentation via un webinaire en direct disponible dans la section Investisseurs & Médias du site de Pliant à l'adresse www.PliantRx.com. L'enregistrement de la présentation restera accessible sur le site pendant 30 jours après la conclusion de l'événement.
Pliant Therapeutics (PLRX) hat seine Teilnahme an der bevorstehenden 43. J.P. Morgan Healthcare Conference bekannt gegeben. Bernard Coulie, M.D., Ph.D., Präsident und CEO des Unternehmens, wird am Dienstag, den 14. Januar 2025, um 13:30 Uhr pazifischer Zeit im Westin St. Francis Hotel in San Francisco eine Präsentation halten.
Interessierte Investoren und Interessengruppen können die Präsentation über einen Live-Webcast auf der Website von Pliant im Bereich Investoren & Medien unter www.PliantRx.com abrufen. Die Aufzeichnung der Präsentation wird 30 Tage nach Abschluss der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.
Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Pliant’s website at www.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
When is Pliant Therapeutics (PLRX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Pliant Therapeutics' (PLRX) J.P. Morgan Healthcare Conference presentation?
How long will Pliant Therapeutics' (PLRX) J.P. Morgan presentation replay be available?